Clinical trials
Recruiting Observational Leukemia, Lymphocytic, Chronic, B-Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 10 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 40 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 3 |
| Dana-Farber Cancer Institute | 3 |
| Mayo Clinic | 3 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| UNC Lineberger Comprehensive Cancer Center | 2 |
| iOMEDICO AG | 2 |
| AbbVie | 1 |
| Alliance for Clinical Trials in Oncology | 1 |
| British Columbia Cancer Agency | 1 |
| Canadian Cancer Trials Group | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 40 |
| Lymphoma, Mantle-Cell | 9 |
| Multiple Myeloma | 9 |
| Leukemia, Myeloid, Acute | 8 |
| Waldenstrom Macroglobulinemia | 8 |
| Lymphoma, B-Cell, Marginal Zone | 7 |
| Lymphoma, Follicular | 7 |
| Lymphoma, Large B-Cell, Diffuse | 7 |
| Lymphoma, Non-Hodgkin | 7 |
| Myelodysplastic Syndromes | 7 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.